- 1. I 123 Monoclonal Antibody 81C6
- [A radioimmunoconjugate of a IgG2 monoclonal antibody (MoAb) 81C6 labeled with iodine 123 (I-123). MoAb 81C6 recognizes the extracellular matrix antigen tenascin (hexabrachion), which is up-regulated in gliomas and other cancers. Using MoAb 81C6 as a carrier for I-123 allows detection of tumor localization and distribution of MoAb 81C6 in diagnostic imaging procedures. ( NCI )] (UMLS (NCI) C0796330) iodine I 123 MOAB 81C6;
Iodine I 123 Monoclonal Antibody 81C6 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 7. I 131 Monoclonal Antibody A33
- [A radioimmunoconjugate of a humanized monoclonal antibody (MoAb) A33 labelled with Iodine 131 (I-131). MoAb A33 recognizes A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, highly and homogenously expressed in 95% of colorectal cancers, with only restricted expression in normal colonic mucosa. Using MoAb A33 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressed A33 antigen. ( NCI )] (UMLS (NCI) C0678093) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
|
- 2. I 124 Monoclonal Antibody A33
- [A radioimmunoconjugate of a humanized monoclonal antibody (MoAb) A33 labelled with Iodine 124 (I-124). MoAb A33 recognizes A33 antigen, a 43 KDa transmembrane glycoprotein of the immunoglobulin superfamily, highly and homogenously expressed in 95% of colorectal cancer metastases, with only restricted expression in normal colonic mucosa. I-124 MoAb A33 delivers beta particle emitting I-124 nuclide directly to metastatic colorectal tissues, thereby could be used in kinetics studies or radioimmunotherapy. ( NCI )] (UMLS (NCI) C0677678) =Amino Acid, Peptide, or Protein; Immunologic Factor; Indicator, Reagent, or Diagnostic Aid
| - 8. I 131 Monoclonal Antibody CC49
- [A radioimmunoconjugate of the humanized monoclonal antibody (MoAB) CC49 labeled with iodine 131 (I-131). MoAb CC49 recognizes the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. I-131 MoAb CC49 delivers beta and gamma radiation emitting I-131 nuclide directly to tumor cells that express TAG-72, thereby allowing imaging and/or treatment of cancers. ( NCI )] (UMLS (NCI) C1327845) Iodine I 131 Monoclonal Antibody CC49;
=Amino Acid, Peptide, or Protein; Pharmacologic Substance ;
|
- 3. I 131 MOAB BC8
- [A radioimmunoconjugate consisting of BC8, a murine IgG1 anti-CD45 monoclonal antibody labeled with iodine 131 (I-131), with radioimmunotherapeutic properties. Using monoclonal antibody BC8 as a carrier for I-131 results in the targeted destruction of cells expressing CD45. CD45 is tyrosine phosphatase expressed on virtually all leukocytes, including myeloid and lymphoid precursors in bone marrow and mature lymphocytes in lymph nodes; it is also expressed on most myeloid and lymphoid leukemic cells, but not on mature erythrocytes or platelets. (NCI04) ( NCI )] (UMLS (NCI) C0796627) I 131 Monoclonal Antibody BC8;
iodine I 131 MOAB BC8;
Iodine I 131 Monoclonal Antibody BC8;
MOAB BC8, iodine I 131;
monoclonal antibody BC8, iodine I 131 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 9. I 131 Monoclonal Antibody G-250
- [A radioimmunoconjugate comprised of the chimeric monoclonal antibody G-250 conjugated with iodine I 131 with potential antineoplastic activity. The antibody moiety of iodine I 131 chimeric monoclonal antibody G-250 binds to G-250, a renal-cell carcinoma-associated antigen, delivering cytotoxic iodine I 131 specifically to renal carcinoma cells that express G-250. ( NCI )] (UMLS (NCI) C0677789) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
|
- 4. I 131 MOAB TNT-1/B
- [An iodine 131 labeled radioimmunoconjugate of monoclonal antibody (MOAB) TNT-1/B with radioimaging and antineoplastic properties. MOAB TNT-1/B was developed for radioimmunotherapy of solid tumors, designated as Tumor Necrosis Treatment (TNT). TNT exploits the presence of degenerating and necrotic cells within tumors by utilizing MOAbs directed against universal, intracellular nucleosomal determinants consisting of histone H1 and DNA. This MOAB was conjugated with biotin (B) molecules, which increase pharmacokinetic performance of the monoclonal antibody. MOAB TNT-1/B delivers I 131 to tumor cells and results in the targeted imaging and/or destruction of cells with exposed necrotic antigens. ( NCI )] (UMLS (NCI) C0879273) I 131 Monoclonal Antibody TNT-1/B;
iodine I 131 MOAB TNT-1/B;
Iodine I 131 Monoclonal Antibody TNT-1/B =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | - 10. I 131 Monoclonal Antibody Lym-1
- [A radioimmunoconjugate of a murine monoclonal antibody, MoAb Lym-1, labeled with iodine 131 (I-131). MoAb Lym-1 recognizes an epitope of the histocompatibility antigen HLA-DR, which is over-expressed on most B-cell lymphomas. I-131 MoAb Lym-1 delivers beta and gamma radiation emitting I-131 nuclide directly to tumor cells that express HLA-DR, thereby allowing imaging and/or treatment of cancers. ( NCI )] (UMLS (NCI) C1134561) Iodine I 131 Monoclonal Antibody Lym-1 =Pharmacologic Substance; Immunologic Factor
|
- 5. I 131 Monoclonal Antibody 3F8
- [A radioimmunoconjugate consisting of 3F8, a murine anti-GD2 ganglioside monoclonal antibody labeled with iodine 131 (I-131), with radioimaging and radioimmunotherapeutic properties. Using monoclonal antibody 3F8 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing GD2. GD2 is a ganglioside which is overexpressed in malignant melanoma, neuroblastoma, and small cell carcinoma of the lung. (NCI04) ( NCI )] (UMLS (NCI) C0393072) =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor
| - 11. Imolamine
- (UMLS (NCI) C0063433) =Organic Chemical; Pharmacologic Substance
|
- 6. I 131 Monoclonal Antibody 81C6
- [A radioimmunoconjugate of a human-murine chimeric IgG2 monoclonal antibody (MoAb) 81C6 labeled with iodine 131 (I-131), with imaging and radioimmunotherapeutic properties. MoAb 81C6 recognizes the extracellular matrix antigen tenascin (hexabrachion), up-regulated in gliomas and other cancers. Using MoAb 81C6 as a carrier for I-131 results in the targeted imaging and/or destruction of cells expressing tenascin. ( NCI )] (UMLS (NCI) C0796329) iodine I 131 MOAB 81C6;
Iodine I 131 Monoclonal Antibody 81C6 =Amino Acid, Peptide, or Protein; Pharmacologic Substance; Immunologic Factor | |
home
